Literature DB >> 14624329

Central administration of nociceptin/orphanin FQ blocks the acquisition of conditioned place preference to morphine and cocaine, but not conditioned place aversion to naloxone in mice.

Kazuto Sakoori1, Niall P Murphy.   

Abstract

RATIONALE: Previous studies have suggested that nociceptin (known also as orphanin FQ) suppresses the rewarding potential of morphine and alcohol in the rat. However, little is known of the effect of nociceptin on the rewarding properties of these and other drugs in the mouse.
OBJECTIVE: To determine the effect of nociceptin on opiate or psychostimulant-induced conditioned place preference, or naloxone-induced conditioned place aversion in mice.
METHODS: C57BL6 mice were implanted with chronically indwelling intracranial cannulae targeted at the lateral cerebroventricle through which nociceptin (0.06, 0.6, or 6 nmol) could be administered. Animals were conditioned in an unbiased balanced paradigm to study the effect of nociceptin administration alone, or the effect of nociceptin on the acquisition of place conditioning to morphine, cocaine, or naloxone (all 7.6 mg/kg subcutaneous).
RESULTS: Administration of 0.06 nmol nociceptin alone stimulated locomotion during conditioning sessions, but had no hedonic effects. In contrast, administration of 6 nmol nociceptin alone markedly reduced basal locomotion during the conditioning sessions and induced a mild place aversion. Both morphine and cocaine induced robust place preferences, the acquisition of which was dose dependently suppressed by administration of nociceptin at doses of 0.6 nmol and above. Conditioning with naloxone produced a robust place aversion that was only weakly blocked by the maximum dose of nociceptin tested.
CONCLUSION: Nociceptin blocks the rewarding properties of drugs in both narcotic analgesic and psychostimulant classes in the mouse. In contrast, nociceptin has only a minor effect on the negative affective state experienced following naloxone administration.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14624329     DOI: 10.1007/s00213-003-1643-3

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  53 in total

Review 1.  Conditioned place preference: what does it add to our preclinical understanding of drug reward?

Authors:  M T Bardo; R A Bevins
Journal:  Psychopharmacology (Berl)       Date:  2000-12       Impact factor: 4.530

Review 2.  Pharmacotherapy of addictions.

Authors:  Mary Jeanne Kreek; K Steven LaForge; Eduardo Butelman
Journal:  Nat Rev Drug Discov       Date:  2002-09       Impact factor: 84.694

Review 3.  Measuring reward with the conditioned place preference paradigm: a comprehensive review of drug effects, recent progress and new issues.

Authors:  T M Tzschentke
Journal:  Prog Neurobiol       Date:  1998-12       Impact factor: 11.685

4.  Intracerebroventricular orphanin FQ/nociceptin suppresses dopamine release in the nucleus accumbens of anaesthetized rats.

Authors:  N P Murphy; H T Ly; N T Maidment
Journal:  Neuroscience       Date:  1996-11       Impact factor: 3.590

5.  Effects of the kappa-opioid receptor agonist U-50,488 on morphine-induced place preference conditioning in the developing rat.

Authors:  C A Bolanos; G M Garmsen; M A Clair; S A McDougall
Journal:  Eur J Pharmacol       Date:  1996-12-12       Impact factor: 4.432

6.  Effects of nocistatin on nociceptin-induced impairment of learning and memory in mice.

Authors:  M Hiramatsu; K Inoue
Journal:  Eur J Pharmacol       Date:  1999-02-19       Impact factor: 4.432

Review 7.  Behavioral phenotypes of inbred mouse strains: implications and recommendations for molecular studies.

Authors:  J N Crawley; J K Belknap; A Collins; J C Crabbe; W Frankel; N Henderson; R J Hitzemann; S C Maxson; L L Miner; A J Silva; J M Wehner; A Wynshaw-Boris; R Paylor
Journal:  Psychopharmacology (Berl)       Date:  1997-07       Impact factor: 4.530

8.  Acquisition, expression, and reinstatement of ethanol-induced conditioned place preference in mice: effects of opioid receptor-like 1 receptor agonists and naloxone.

Authors:  A Kuzmin; J Sandin; L Terenius; S O Ogren
Journal:  J Pharmacol Exp Ther       Date:  2003-01       Impact factor: 4.030

9.  Motivational properties of kappa and mu opioid receptor agonists studied with place and taste preference conditioning.

Authors:  R F Mucha; A Herz
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

View more
  42 in total

1.  The first universal opioid ligand, (2S)-2-[(5R,6R,7R,14S)-N-cyclopropylmethyl-4,5-epoxy-6,14-ethano-3-hydroxy-6-methoxymorphinan-7-yl]-3,3-dimethylpentan-2-ol (BU08028): characterization of the in vitro profile and in vivo behavioral effects in mouse models of acute pain and cocaine-induced reward.

Authors:  Taline V Khroyan; Willma E Polgar; Gerta Cami-Kobeci; Stephen M Husbands; Nurulain T Zaveri; Lawrence Toll
Journal:  J Pharmacol Exp Ther       Date:  2010-12-21       Impact factor: 4.030

Review 2.  Nociceptin Opioid Receptor (NOP) as a Therapeutic Target: Progress in Translation from Preclinical Research to Clinical Utility.

Authors:  Nurulain T Zaveri
Journal:  J Med Chem       Date:  2016-03-14       Impact factor: 7.446

3.  Regarding "Buprenorphine reduces alcohol drinking through activation of the nociceptin/orphanin FQ-NOP receptor system".

Authors:  David A Gorelick
Journal:  Biol Psychiatry       Date:  2007-05-25       Impact factor: 13.382

4.  Agonist-antagonist combinations in opioid dependence: a translational approach.

Authors:  P Mannelli
Journal:  Dipend Patologiche       Date:  2010

5.  A Novel and Selective Nociceptin Receptor (NOP) Agonist (1-(1-((cis)-4-isopropylcyclohexyl)piperidin-4-yl)-1H-indol-2-yl)methanol (AT-312) Decreases Acquisition of Ethanol-Induced Conditioned Place Preference in Mice.

Authors:  Nurulain T Zaveri; Paul V Marquez; Michael E Meyer; Willma E Polgar; Abdul Hamid; Kabirullah Lutfy
Journal:  Alcohol Clin Exp Res       Date:  2018-01-19       Impact factor: 3.455

6.  Nociceptin Receptors Upregulated in Cocaine Use Disorder: A Positron Emission Tomography Imaging Study Using [11C]NOP-1A.

Authors:  Rajesh Narendran; Savannah Tollefson; Michael L Himes; Jennifer Paris; Brian Lopresti; Roberto Ciccocioppo; N Scott Mason
Journal:  Am J Psychiatry       Date:  2019-05-06       Impact factor: 18.112

7.  Comparison of the antinociceptive and antirewarding profiles of novel bifunctional nociceptin receptor/mu-opioid receptor ligands: implications for therapeutic applications.

Authors:  Lawrence Toll; Taline V Khroyan; Willma E Polgar; Faming Jiang; Cris Olsen; Nurulain T Zaveri
Journal:  J Pharmacol Exp Ther       Date:  2009-09-22       Impact factor: 4.030

Review 8.  Nociceptin/Orphanin FQ Receptor Structure, Signaling, Ligands, Functions, and Interactions with Opioid Systems.

Authors:  Lawrence Toll; Michael R Bruchas; Girolamo Calo'; Brian M Cox; Nurulain T Zaveri
Journal:  Pharmacol Rev       Date:  2016-03-08       Impact factor: 25.468

9.  Novel role of the nociceptin system as a regulator of glutamate transporter expression in developing astrocytes.

Authors:  Logan C Meyer; Caitlin E Paisley; Esraa Mohamed; John W Bigbee; Tomasz Kordula; Hope Richard; Kabirullah Lutfy; Carmen Sato-Bigbee
Journal:  Glia       Date:  2017-09-14       Impact factor: 7.452

10.  The role of NOP receptors in psychomotor stimulation and locomotor sensitization induced by cocaine and amphetamine in mice.

Authors:  Paul Marquez; Abdul Hamid; Kabirullah Lutfy
Journal:  Eur J Pharmacol       Date:  2013-03-21       Impact factor: 4.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.